Skip to main content
OpenTrials
Completed

NCT Number: NCT04987476

Rhabdoid Tumors Cellular Architecture by Single-cell Analyses (InnovRT-2)

The aim is to describe at the cellular level the heterogeneity of rhabdoid tumors, and identify how this diversity influences resistance to treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

Up to 17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Curie

Paris, 75005, France

About this study

Rhabdoid tumors are aggressive cancers of infancy. Although frequently chemosensitive at the very beginning, they very often show resistance, suggesting some intra-tumor diversity or plasticity. Moreover, morphological analysis of rhadoid tumors often reveal some variety in tumor cell shapes and immunohistochemical profiling. Altogether, this suggests some intra-tumor heterogeneity, that has been scarcely studied so far.

This project aims to describe the intra-tumor heterogeneity by single-cell sequencing approaches.

After surgical resection, fresh tumor samples will be dissected and analysed using the 10X Chromium technology. Briefly, cells will be grouped in clusters according to their gene expression signalling, and each cluster will be defined in comparison with all other ones. Differential analyses will allow identifying the main characteristic of each cell sub-population. Potential filiations between clusters will be analysed using classical algorithms. The study will be performed on 10 to 15 tumor samples.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 0-17 years old
  • having a rhabdoid tumor according to clinical and radiological features Or likely having a rhabdoid tumor according to clinical and radiological features
  • surgical resection in standard care
  • sufficient material for both diagnosis and experimental procedures
  • parents' agreement

Treatment and study plan

analyzes in singles cells

Biological

genome expression analyzes in single cells

Primary outcomes

  1. Intra-tumor heterogeneity

    Time frame: Inclusion

    Identification of cell clusters - mean expression (RPKM unit) of gene set signtaures in each bioinformatically defined cluster

Secondary outcomes

  1. Cell clusters recurrent from one sample to the other

    Time frame: Inclusion

    Fraction/percentage of cell clusters defined by primary outcome that are specific to each tumor and those that are shared by several or all samples

  2. Naming of potential targetable gene

    Time frame: Inclusion

    Mean expression (RPKM unit) of targetable genes (defined by the existence of adequate pharmacological inhibitor) in each tumor sample and clusters

  3. Identification of cytotoxic cells

    Time frame: Inclusion

    Conducting therapeutic biological functional tests

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Institut Curie
  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Hétérogénéité Des Tumeurs Rhabdoides : Approches en " Cellules Uniques " Pour Identifier Des Cibles thérapeutiques

Acronym: InnovRT-2

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Aug 3, 2021
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.